Testing effectiveness (Phase 2)Study completedNCT05508867
What this trial is testing
Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Who this might be right for
Hodgkin Lymphoma
Merck Sharp & Dohme LLC 203